A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
Vaccine primes dendritic cells to activate antigen-specific CD8+ T cells, which kill tumor cells presenting the tumor peptide on HLA-A via perforin/granzyme; HLA-A itself is not the cytotoxic target.
A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
The vaccine delivers peptides to dendritic cells, activating CD8+ T cells that kill tumor cells presenting specific peptide–MHC I complexes via perforin/granzyme apoptosis. HLA-B itself is just the presenting molecule and is not the cytotoxic target.
A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
ATP150 primes CD8+ T cells by delivering tumor antigen peptides to dendritic cells; the resulting CTLs kill tumor cells presenting those peptides on MHC I via perforin/granzyme. HLA-C itself is not the target of killing.
A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
ATP150 delivers antigens to dendritic cells for MHC I/II presentation, activating tumor-specific T cells that kill tumor cells. HLA-DR–expressing APCs are not directly targeted or killed by the drug or engaged effector cells.
A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
The vaccine delivers antigens to HLA-DP–expressing dendritic cells for presentation to CD4+ T cells, which helps activate CD8+ cytotoxic T cells. The resulting CTLs kill tumor cells presenting the vaccine peptides on MHC I via perforin/granzyme or Fas–FasL pathways; HLA-DP–positive APCs are not directly killed.